Sutro Biopharma Inc. (STRO)
Company Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.
It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.
It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology.
The company was formerly known as Fundamental Applied Biology, Inc.
Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Country | United States |
IPO Date | Sep 27, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 310 |
CEO | Jane Chung R.Ph. |
Contact Details
Address: 111 Oyster Point Boulevard South San Francisco, California United States | |
Website | https://www.sutrobio.com |
Stock Details
Ticker Symbol | STRO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001382101 |
CUSIP Number | 869367102 |
ISIN Number | US8693671021 |
Employer ID | 45-2441988 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Jane Chung R.Ph. | Chief Executive Officer & Director |
Edward C. Albini M.B.A | Chief Financial Officer & Secretary |
David Pauling J.D., M.A. | General Counsel |
Dr. Anne Elizabeth Borgman-Hagey M.D. | Chief Medical Officer |
Dr. Barbara Leyman Ph.D. | Chief Business Development Officer |
Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer |
Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder |
Dr. Venkatesh Srinivasan Ph.d. | Chief Technical Operations Officer |
Linda A. Fitzpatrick | Chief People & Communications Officer |
Regina Cheng | Vice President & Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 13, 2025 | 10-K | Annual Report |
Mar 13, 2025 | 8-K | Current Report |
Mar 07, 2025 | 4 | Filing |
Mar 07, 2025 | 4 | Filing |
Mar 07, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Mar 04, 2025 | 4 | Filing |
Mar 04, 2025 | 4 | Filing |